Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Former US Army Sgt. Mark Millich’s sex drive plummeted — and his genitals shrank and changed shape after taking popular hair-loss drug finasteride.

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...

Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.

Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

The second group, so-called "Constrained Losers," are those hard-to-short stocks that have lost the most over the trailing year. The professors found that these stocks also lag the market, but for a ...

Within six months, former US Army sergeant Mark Millich began experiencing dizziness, fatigue, cold sweats and was slurring his words - which he described it as feeling 'lobotomized'.

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...